Sunday, January 24, 2021
Home Latest Pharma-News Oncimmune signs contract with Genentech to profile samples from rheumatology trials

Oncimmune signs contract with Genentech to profile samples from rheumatology trials

September 2020: “Oncimmune Holdings, the leading global immunodiagnostics group, has announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus.

In this new project, Oncimmune will use its proprietary NavigAID™ panel to characterise autoantibody profiles from trial participants.

- Advertisement -

Following completion of this project, Genentech has the option to expand the contract to profile additional samples.

SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time.

Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy.

This project builds upon Oncimmune’s broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune’s ImmunoINSIGHTS service business.”

https://www.directorstalkinterviews.com/oncimmune-signs-contract-with-genentech-further-demonstrating-expanding-global-footprint-for-immunoinsights/412860165#:~:text=Oncimmune%20Holdings%20plc%20(LON%3AONC,diseases%2C%20including%20Systemic%20Lupus%20Erythematosus.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2 × 2 =

Most Popular

What is the process for Submission of Synopsis?

1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

COVAX Announces new agreement, plans for first deliveries

January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...

FDA Approves OPDIVO® with CABOMETYX® as First-line Treatment for advanced Renal Cell Carcinoma

22 Jan 2021:  Bristol Myers Squibb announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks...

FDA granted approval of Cabenuva and Vocabria to ViiV Healthcare for HIV

January 21, 2021: "The U.S. FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human...